NextFin News - CVC Capital Partners and Groupe Bruxelles Lambert (GBL) have submitted a non-binding proposal to acquire the remaining shares of Recordati SpA, valuing the Italian pharmaceutical mainstay at approximately €10.9 billion ($12 billion). The offer, priced at €52 per share, represents a strategic move to take the Milan-listed company private after nearly a century of operation and eight years of private equity involvement.
The consortium, led by CVC, already holds a controlling interest of roughly 51.8% in Recordati through a holding vehicle. By offering to buy out the minority shareholders, the private equity firm aims to delist the company from the Borsa Italiana, providing more flexibility for long-term restructuring and expansion without the scrutiny of public markets. Recordati confirmed on Friday that it had received the indication of interest but noted that its corporate bodies have not yet formally reviewed the proposal. The deal remains subject to several conditions, including due diligence and the finalization of financing arrangements.
Recordati has evolved significantly since CVC first acquired its majority stake in 2018 for approximately €3 billion. Under private equity stewardship, the company has pivoted toward high-margin specialty medicines and rare diseases. Its flagship therapy for Cushing’s disease, Isturisa, has become a cornerstone of its portfolio, with analysts at GlobalData projecting sales for the drug to reach nearly $1 billion by 2031. This shift from traditional primary care to orphan drugs has made Recordati an attractive target for a full take-private transaction, as the rare disease market often commands premium pricing and faces less generic competition.
The involvement of GBL, the Belgian investment holding company, underscores the scale of the capital required for the buyout. GBL has a history of partnering on large-scale European industrial and healthcare deals, often taking a long-term "permanent capital" approach that contrasts with the typical five-to-seven-year horizon of traditional private equity funds. This partnership suggests a strategy focused on consolidating Recordati’s position in the fragmented European mid-cap pharma sector through further bolt-on acquisitions.
However, the €52 per share offer may face resistance from minority investors who view the premium as insufficient given Recordati’s recent growth trajectory. Some market participants argue that the current valuation does not fully account for the "peak sales" potential of the company’s newer rare disease pipeline. While CVC’s existing control makes a rival bid unlikely, the success of the delisting will depend on whether institutional shareholders believe the offer reflects the company’s intrinsic value in a high-interest-rate environment where healthcare assets remain a preferred defensive play.
The proposed transaction also highlights a broader trend of "take-private" deals in the European healthcare sector, where valuations have occasionally lagged behind their U.S. peers. For the Italian market, the departure of a blue-chip name like Recordati would be a blow to the Milan exchange’s liquidity, yet it reflects the reality of a global pharmaceutical landscape where scale and specialized portfolios are increasingly managed away from the volatility of daily equity trading. The board’s upcoming review will determine whether this century-old family-founded business begins its next chapter entirely behind closed doors.
Explore more exclusive insights at nextfin.ai.
